Targeting T cells for GVHD therapy

Seminars in Cancer Biology

Volumn 7, Issue 2, 1996, Pages 57-64

  Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone marrow transplantation; Graft versus host disease; Immunotoxins; Mice; Therapy

Indexed keywords

CD3 ANTIGEN; CORTICOSTEROID; HYBRID PROTEIN; IMMUNOTOXIN; THYMOCYTE ANTIBODY;

BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0029932616     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1996.0009     Document Type: Review

References (57)

1. Atkinson K (1994) Clinical bone marrow transplantation: a reference textbook. Cambridge University Press, Cambridge
2. Waldmann H, Cobbold S, Hale G (1994) What can be done to prevent graft versus host disease? Curr Biol 6:777-783
3. Bron D (1994) Graft-versus-host-disease. Curr Sci 6:358-364
4. Weisdorf D, Haake D, Blazar BR, Miller W, McGlave P, Ramsya NR, Kersey J, Gilipovich A (1990) Treatment of moderate/ severe acute graft-versus-host disease following allogeneic bone marrow transplantation: An analysis of clinical risk factors and outcome. Blood 75:1024
5. Korngold R, Sprent J (1987) T cell subsets and graft-versus-host disease. Transplantation 44:335
6. Korngold R, Sprent J (1985) Surface markers of T-cells causing lethal graft-versus-host disease to class I vs class II H-2 differences. J Immunol 135:3004
7. Vallera DA, Soderling CCB, Kersey JH (1982) Bone marrow transplantation across major histocompatibility barriers in mice: III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. J Immunol 128:871
8. Pietryga DW, Blazar BR, Soderling CCB, Vallera DA (1987) The effect of T-subset depletion on the incidence of lethal graft-versus-host disease in a murine major histocompatibility complex mismatched transplantation system. Transplantation 43:442
9. Cantor H (1972) The effects of anti-theta antiserum upon graft-versus-host activity of spleen and lymph node cells. Cell Immunol 3:461
10. Rodt HV, Thierfelder S, Eulitz M (1972) Suppression of acute secondary disease by heterologous anti-brain serum. Blut 25:385
11. Tyan ML (1973) Modification of severe graft-versus-host disease with antiserum to the theta antigen or to whole serum. Transplantation 15:601
12. Vallera DA, Youle RJ, Neville DM, Kersey JH (1982) Bone marrow transplantation across major histocompatibility barriers: V Protection of mice from lethal GVHD by pretreatment of donor cells with monoclonal anti-Thy1.2 coupled to the toxin ricin. J Exp Med 155:949
13. Vallera D, Ash R, Zanjani E, Kersey J, LeBien T, Beverly R, Neinke D, Youle R (1983) Anti-T cell reagents for human bone marrow transplantation: ricin linked to three modern antibodies. Science 1222:512-515
14. Filipovich AH, Vallera DA, McGlave P, Polich D, Gajl-Peczalska K, Haake R, Lasky L, Blazar BR, Ramsay NKC, Kersey J, Weisdorf D (1990) T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation: The correlation between residual CD5 negative T cells and subsequent GVHD. Transplantation 50:410-415
15. Vallera DA, Blazar BR (1989) T-cell depletion for graft-versus-host disease (GVHD) prophylaxis: A perspective on engraftment in mice and humans. Transplantation 47:751-760
16. Martin PJ, Hansen JA, Torok-Storb B, Moretti L, Press O, Storb R, Thomas ED, Weiden PL, Vitetta ES (1988) Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplantation 3:437-444
17. Truitt RL, Shih CC-Y, LeFever AV, Tempelis LD, Andreani M, Bortin MM (1983) Characterization of alloimmunization induced T lymphocytes-reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vivo. J Immunol 131:2050
18. Giralt SA, Champlin RE (1994) Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603
19. Alexander P (1981) Treatment of acute leukaemia by whole-body irradiation and marrow transplantation: 25 years from mouse to man. Br Med J ii:626
20. Vallera DA (1994) Immunotoxins: Will their clinical promise be fulfilled? Blood 83:309
21. Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA (1991) In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T-cell depleted marrow for the promotion of engraftment. J Immunol 147:1492
22. Martin PJ, Schoch G, Fisher L (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76:1464
23. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK, Kersey JH, Weisdorf DJ (1992) Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplantation 10:77-82
24. Atkinson K (1990) Clinical spectrum of human chronic graft-versus-host disease, in Graft-vs-Host disease (Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds) vol.68, pp 569-586. Marcel Dekker, Inc; New York and Basel
25. Blazar BR, Soderling CCB, Koo GC, Vallera DA (1988) Absence of a facilitory role for NK 1.1 positive donor cells in engraftment across a major histocompatibility barrier in mice. Transplantation 45:876
26. Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA (1993) Non-mitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier. J Immunol 150:265-277
27. Blazar BR, Taylor PA, Vallera DA (1994) In vivo or in vitro anti-CD3 chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. J Immunol 152:3665
28. Vallera D, Schmidberger H, Buchsbaum D, Everson P, Blazar B (1991) Radiotherapy in mice with Yttrium-90 labeled anti-Ly1 monoclonal antibody: Therapy of established graft-versus-host disease induced across the major histocompatibility barrier. Cancer Res 15:1891
29. Vallera DA, Carroll SF, Snover D, Carlson GJ, Blazar BR (1991) Toxicity and efficacy of anti-T cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease across the major histocompatibility barrier. Blood 77:182
30. Byers VS, Henslee J, Kernan N, Blazar BR, Gingrich R, Phillips GL, Lemaistre CF, Gilliland G, Antin JH, Vogelsang G, Martin P, Tutschka PJ, Trown P, Ackerman SK, O'Reilly RJ, Scannon PJ (1990) Use of anti-pan T lymphocyte ricin A chain immunotoxin as targeted immunotherapy in steroid resistant acute graft-versus-host disease. Blood 75:1426-1432
31. Blazar BR, Taylor PA, Sehgal SN, Vallera DA (1992) Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process. Ann NY Acad Sci 685:73
32. Sehgal SN, Baker H, Verzina C (1975) Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization. J Antibiotics 28:727-732
33. Verina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiotics 28:721-726
34. Bierer BE, Matilla PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL (1990) Two distinct signal transmission pathways in T lymphoscytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Nat: Acad Sci 87:9231-9235
35. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fisher PA, Sigal NH (1990) The immunosuppressive macorlides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 144:1418-1424
36. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, DePauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C (1989) Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplant 47:606
37. Alegre ML, Vandenbeele P, Depierreux M, Florquin S, Deschodt-Lanckman M, Flamand V, Moser M, Leo O, Urbain J, Fiers W, Goldman M (1991) Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: Prevention by high doses of methylprednisolone. J Immunol 146:1185
38. Ferrand C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach JF, Chatenoud L (1990) Cytokine related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation. Eur J Immunol 20:509
39. Flamand V, Abramowicz D, Goldman M, Biernaux C, Huez G, Urbain J, Moser M, Leo O (1990) Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 144:2875
40. Hirsch R, Gress RE, Plutnik DH, Eckhaus M, Bluestone JA (1989) Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. In vivo activation of T cells. J Immunol 142:737
41. Derocq JM, Casellas P, Laurent G, Ravel S, Vidal H, Jansen F (1988) Comparison of the cytotoxic potency of T101 Fav, F(ab')2 and whole IgGF immunotoxins. J Immunol 141:2837-2843
42. Masuho Y, Kishida K, Saito M, Umemoto N, Hara T (1982) Importance of the antigen-binding valency and the nature of the cross-linking bond in ricin A-chain conjugates with antibody. J Biochem 91:1583-1591
43. Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G, Amlot P, Vitetta KE, Thorpe P (1988) Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 48:2610-2617
44. Ravel S, Casellas P (1990) Internalization of the cytotoxic molecules of T101 F(ab')2-(ricin-A-chain) immunotoxin into human T-leukemic cells. Eur J Biochem 192:469-473
45. Ross WCJ, Thorpe PE, Cumber AJ, Edwards DC, Hinson CA, Davies AJS (1980) Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab') 2 fragment. Eur J Biochem 104:381-390
46. Vallera DA, Taylor PA, Panoskaltsis-Mortari A, Blazar BR (1995) Therapy of ongoing graft-versus-host disease (GVHD) induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-RTA (ricin toxin A chain) immunotoxin. Blood 86:4367
47. Preijers FWMB, DeWitte T, Rijke-Schilder GPM, Tax WJM, Wessels JMC, Haanen C, Capel PJA (1988) Human T lymphocyte differentiation antigens as target for immunotoxins or complement-mediated cytotoxicity. Scand J Immunol 28:185-194
48. Press OW, Vitetta ES, Farr AG, Hansen JA, Martin PJ (1986) Evaluation of ricin A-chain immunotoxins directed against human T cells. Cell Immunol 102:10-20
49. Manske JM, Buchsbaum DJ, Vallera DA (1989) The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. J Immunol 142:1755
50. Bierer BE, Burakoff SJ, Smith BR (1989) A large proportion of T lymphocytes lack CD5 expression after bone marrow transplantation. Blood 73:1359
51. Bierer BE, Nishimura Y, Burakoff SJ, Smith BR (1988) Phenotypic and functional characterization of human cytolytic T cells lacking expression of CD5. Clin Invest 81:1390
52. Antin JH, Ferrara LM (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964-2968
53. Vallera DA, Taylor PA, Vannice JL, Panoskaltsis-Mortari A, Blazar BR (1995) IL-1 or TNF-a antagonist do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice. Transplantation 60:1371
54. Blazar BR, Taylor PA, Gray GS, Vallera DA (1995) The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility (miH)-disparate donor inocula. Transplantation 58:1422-1426
55. Vitetta E, Thorpe PE, Uhr JW (1993) Immunotoxins: Magic bullets or misguided missiles? Immunology Today 14:252
56. Vallera DA, Eide CR, Jost CR, Blazar BR (1995) Targetting murine T cells with a scFV fusion protein directed against CD3e. 4th International Symposium on Immunotoxins
57. Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA (1995) A murine cytokine fusion toxin specifically targeting the murine GM-CSF receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells. Blood 86:2732